Phenotype-Specific Response Patterns to IL-23 Inhibition in Hidradenitis Suppurativa: Pooled Secondary Analysis of Guselkumab and Risankizumab Phase 2 Clinical Trials Journal of the American Academy of Dermatology

Supplementary Data Tables and Methods